To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Doripenem
Doripenem is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup of carbapenems. It was launched by Shionogi Co. of Japan under the brand name Finibax in 2005. It is particularly active against Pseudomonas aeruginosa. Product highlightDoripenem was approved by the United States Food and Drug Administration on October 12, 2007, to be sold under the tradename Doribax.[1] References
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Doripenem". A list of authors is available in Wikipedia. |
- Organ_replacement_in_animals
- Agilent Technologies Tools Used to Derive New Type of Mouse Embryonic Stem Cell that Shares Key Features of Human Embryonic Stem
- Allan_Wilson
- We might not know half of what’s in our cells, new AI technique reveals - Artificial intelligence-based technique reveals previously unknown cell components that may provide new clues to human development and disease
- Silver_nitrate